A Phase 4 interventional study of Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution in Dehydration, sponsored by Baxter Healthcare Corporation. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-24.
Sponsored by Baxter Healthcare Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Dehydration with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Dehydration · United States.
Among the 87 studies in Dehydration with a site in United States, this one is the 49th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 4, and was the 12th registered.
201 studies on the registry are indexed under Dehydration; 28 are open to participants now.
Browse Dehydration studies →7 of the 87 studies in Dehydration with a site in United States are open now. Recruiting first, the newest first:
State University of New York at Buffalo · Sites in United States
Ages 18–60
PepsiCo Global R&D · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Duquesne University · Sites in United States
Ages 60+ · Healthy volunteers
University of Iowa · Sites in United States
Ages 18–60
Arizona State University · Sites in United States
Ages 20–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Dehydration studies recruiting now, 7 (47%) set no upper age limit and 7 (47%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3 · Phase 4 6
First in 2005; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 44 across 145 interventional studies indexed under Dehydration.
Median enrollment 30 across the 74 interventional studies, 82 across the 13 observational. Of the 73 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 87 have an industry lead sponsor. The 10 most frequent:
Baxter Healthcare Corporation is the lead sponsor of 80 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Baxter Healthcare Corporation has 5 studies filed under Dehydration — fewer than ten, so there is no comparison to draw.
5 of the studies in Dehydration with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653620PepsiCo Global R&DHydration & Female Life Stages | 2026-11 |
| NCT06847256University of IowaGenetic Risk Factor for Heat Stroke | 2026-12 |
| NCT07641361State University of New York at BuffaloHydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy | 2027-02-01 |
| NCT07658820Arizona State UniversityThe Role of Carbohydrate Blends and Electrolytes on Physical and Mental Performance During Cycling in the Heat | 2027-03-30 |
| NCT02253238M.D. Anderson Cancer CenterSensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 87 studies in Dehydration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lactated Ringer's solution fluid is also being evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Drug page: Hyaluronidase (human recombinant)
Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
Also known as: rHuPH20, LR solution
Maximum Measured In-line Fluid Pressure
Maximum fluid pressure measured (15 sec period) in delivery line during subcutaneous fluid infusion at specified time point after start of infusion
Time frame: each minute for the first 15 minutes of fluid infusion, every 5 minutes for the next 45 minutes of infusion, and every 15 minutes thereafter until the end of infusion
Number of Attempts Needed for Successful Subcutaneous Catheter/Needle Placement
Time frame: end of catheter/needle placement
Cumulative Fluid Volume Delivered
Time frame: each minute for the first 15 minutes of fluid infusion, every 5 minutes for the next 45 minutes of infusion, and every 15 minutes thereafter until the end of infusion
Technical Challenges Encountered During Fluid Infusion
Observed challenges, including catheter kinking, catheter/needle dislodgement/pull-out, infusion pump alarm, other technical problems
Time frame: at any occurence of a defined challenge or at end of infusion if no challenges occurred
| Milestone | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 3 |
| Completed | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum fluid pressure measured (15 sec period) in delivery line during subcutaneous fluid infusion at specified time point after start of infusion
| psi | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme |
|---|---|---|---|---|---|---|---|---|
| 1 min | 6.9 (2.6 to 11.1) | 3.0 (2.6 to 3.5) | 6.8 (3.1 to 10.6) | 5.0 (1.5 to 11.7) | 3.8 (3.7 to 3.8) | 2.8 (2.8 to 2.8) | 1.1 (1.0 to 1.2) | 3.0 (1.5 to 5.1) |
| 2 min | 6.8 (2.8 to 10.8) | 2.4 (2.1 to 2.7) | 7.8 (3.3 to 12.3) | 5.9 (1.0 to 14.2) | 4.1 (3.8 to 4.4) | 3.1 (3.1 to 3.1) | 1.1 (0.9 to 1.4) | 2.4 (1.1 to 4.7) |
| 3 min | 6.7 (2.8 to 10.6) | 2.1 (1.9 to 2.5) | 7.4 (3.5 to 11.2) | 6.1 (1.3 to 14.9) | 4.2 (4.1 to 4.4) | 3.2 (3.2 to 3.2) | 1.2 (1.1 to 1.3) | 2.5 (1.0 to 4.9) |
| 4 min | 6.6 (2.8 to 10.4) | 2.1 (1.8 to 2.5) | 7.3 (3.7 to 11.0) | 6.0 (1.0 to 15.9) | 4.3 (4.3 to 4.3) | 3.2 (3.2 to 3.2) | 1.0 (1.0 to 1.1) | 2.8 (1.6 to 4.7) |
| 5 min | 6.1 (2.7 to 9.5) | 2.6 (1.8 to 4.1) | 9.1 (7.7 to 10.6) | 5.7 (1.0 to 15.1) | 4.4 (4.3 to 4.4) | 3.2 (3.2 to 3.2) | 1.1 (1.1 to 1.1) | 2.5 (1.1 to 4.9) |
| 6 min | 6.2 (2.8 to 9.6) | 3.3 (1.8 to 6.0) | 8.0 (4.9 to 11.1) | 7.1 (1.4 to 18.4) | 4.1 (4.0 to 4.2) | 3.2 (3.2 to 3.2) | 2.2 (2.1 to 2.2) | 2.4 (2.2 to 2.5) |
| 7 min | 6.2 (2.8 to 9.7) | 3.2 (1.9 to 5.7) | 8.8 (3.4 to 14.1) | 7.1 (1.6 to 17.8) | 4.1 (4.1 to 4.2) | 3.2 (3.2 to 3.2) | 2.1 (2.1 to 2.2) | 3.8 (2.2 to 6.9) |
| 8 min | 6.4 (2.8 to 10.1) | 3.6 (2.0 to 5.9) | 9.0 (3.7 to 14.4) | 7.3 (2.8 to 16.1) | 4.2 (4.1 to 4.3) | 3.2 (3.2 to 3.2) | 2.1 (2.1 to 2.2) | 4.6 (2.1 to 7.6) |
| 9 min | 6.5 (2.8 to 10.2) | 3.8 (2.0 to 6.8) | 8.2 (2.9 to 13.5) | 7.0 (2.5 to 14.5) | 4.2 (4.2 to 4.2) | 3.2 (3.2 to 3.2) | 2.2 (2.1 to 2.3) | 4.1 (2.1 to 7.9) |
| 10 min | 6.5 (2.8 to 10.2) | 3.9 (1.9 to 6.7) | 7.7 (2.9 to 12.5) | 6.2 (2.4 to 12.6) | 4.1 (4.1 to 4.2) | 3.2 (3.2 to 3.2) | 2.2 (2.1 to 2.3) | 3.9 (2.1 to 7.4) |
| 11 min | 6.5 (2.7 to 10.3) | 3.7 (2.0 to 6.5) | 11.9 (5.5 to 18.2) | 7.6 (2.7 to 14.5) | 4.1 (4.0 to 4.2) | 3.2 (3.2 to 3.2) | 4.0 (3.9 to 4.0) | 6.4 (2.1 to 12.8) |
| 12 min | 6.7 (2.7 to 10.6) | 4.2 (1.6 to 8.9) | 13.6 (4.3 to 22.9) | 10.3 (2.2 to 21.2) | 4.1 (4.1 to 4.2) | 3.2 (3.2 to 3.2) | 3.8 (3.7 to 3.9) | 7.4 (2.1 to 13.0) |
| 13 min | 6.7 (2.7 to 10.7) | 3.6 (1.7 to 7.2) | 7.7 (3.1 to 12.2) | 10.5 (2.3 to 18.8) | 4.1 (4.0 to 4.2) | 3.2 (3.2 to 3.2) | 3.9 (3.8 to 4.0) | 7.0 (3.8 to 12.8) |
| 14 min | 6.6 (2.7 to 10.5) | 3.0 (1.7 to 5.2) | 3.5 (2.6 to 4.4) | 17.7 (2.1 to 34.2) | 4.1 (4.0 to 4.2) | 3.3 (3.3 to 3.3) | 3.6 (3.4 to 3.9) | 6.9 (3.8 to 11.4) |
| 15 min | 7.3 (3.5 to 11.0) | 4.0 (2.0 to 5.8) | 3.4 (2.6 to 4.2) | 15.8 (2.1 to 34.1) | 4.1 (4.1 to 4.2) | 3.2 (3.2 to 3.2) | 3.7 (3.5 to 3.9) | 6.5 (3.8 to 11.8) |
| 20 min | 7.3 (3.1 to 11.5) | 2.2 (1.7 to 3.0) | 3.3 (2.7 to 3.9) | 11.9 (1.8 to 26.3) | 4.1 (4.0 to 4.3) | 3.2 (3.2 to 3.2) | 3.6 (3.5 to 3.7) | 6.2 (3.8 to 10.9) |
| 25 min | 6.8 (3.1 to 10.4) | 2.4 (2.2 to 2.9) | 3.0 (2.0 to 4.1) | 8.7 (1.7 to 21.3) | 4.8 (4.3 to 5.4) | 3.2 (3.2 to 3.2) | 3.7 (3.7 to 3.8) | 6.1 (3.6 to 10.1) |
| 30 min | 5.8 (3.3 to 8.3) | 2.2 (1.8 to 2.8) | 8.4 (2.1 to 14.8) | 8.6 (1.7 to 21.2) | 4.8 (4.8 to 4.9) | 3.2 (3.2 to 3.2) | 3.8 (3.5 to 4.0) | 5.8 (3.6 to 9.8) |
| 35 min | 6.5 (3.3 to 9.8) | 2.7 (1.8 to 4.0) | 2.9 (2.0 to 3.9) | 10.9 (2.3 to 19.5) | 4.5 (4.5 to 4.5) | 3.3 (3.3 to 3.3) | 4.2 (3.4 to 5.1) | 6.4 (3.6 to 12.0) |
| 40 min | 7.0 (3.2 to 10.9) | 2.2 (2.1 to 2.3) | 2.9 (2.0 to 3.8) | 11.5 (2.1 to 20.8) | 4.6 (4.5 to 4.6) | 3.2 (3.2 to 3.2) | 3.4 (3.4 to 3.4) | 5.9 (3.6 to 10.6) |
| 45 min | 6.6 (2.8 to 10.4) | 2.3 (2.0 to 2.6) | 2.9 (2.0 to 3.9) | 7.4 (1.7 to 18.6) | 4.3 (4.1 to 4.6) | 3.2 (3.2 to 3.2) | 3.4 (3.3 to 3.5) | 5.8 (3.6 to 10.0) |
| 50 min | 6.4 (2.7 to 10.0) | 2.2 (1.8 to 2.6) | 3.0 (1.9 to 4.1) | 7.8 (1.6 to 19.8) | 4.5 (4.5 to 4.5) | 3.3 (3.3 to 3.3) | 3.4 (3.3 to 3.5) | 5.8 (3.5 to 10.1) |
| 55 min | 5.3 (2.8 to 7.9) | 2.4 (2.2 to 2.6) | 2.9 (1.9 to 3.8) | 7.9 (2.1 to 19.0) | 4.4 (4.3 to 4.5) | 3.2 (3.2 to 3.2) | 3.4 (3.2 to 3.5) | 6.0 (3.5 to 10.9) |
| 60 min | 5.3 (2.9 to 7.7) | 3.1 (1.9 to 4.3) | 2.9 (2.0 to 3.8) | 7.7 (1.5 to 19.3) | 3.7 (3.6 to 3.8) | 3.2 (3.2 to 3.2) | 3.4 (3.3 to 3.4) | 6.5 (3.5 to 12.2) |
| 75 min | 4.6 (2.6 to 6.7) | 2.6 (2.3 to 3.2) | 2.3 (1.8 to 2.8) | 5.9 (1.5 to 14.2) | 3.6 (3.0 to 4.1) | 2.8 (2.8 to 2.8) | 2.6 (2.6 to 2.7) | 7.8 (2.8 to 16.1) |
| 90 min | 4.1 (2.9 to 5.3) | 3.6 (2.4 to 4.5) | 2.1 (1.6 to 2.7) | 4.0 (1.3 to 8.9) | 3.5 (3.0 to 4.0) | 2.7 (2.7 to 2.7) | 2.7 (2.6 to 2.8) | 7.5 (2.7 to 16.7) |
| 105 min | 5.0 (2.9 to 7.1) | 2.7 (2.1 to 3.2) | 2.2 (1.7 to 2.7) | 4.5 (1.2 to 10.5) | 4.0 (3.1 to 4.9) | 2.7 (2.7 to 2.7) | 2.6 (2.6 to 2.6) | 6.3 (2.7 to 13.0) |
| 120 min | 3.4 (2.7 to 4.1) | 2.6 (1.9 to 3.6) | 2.5 (1.5 to 3.4) | 5.2 (1.2 to 12.6) | 4.3 (3.5 to 5.1) | 2.9 (2.9 to 2.9) | 2.8 (2.6 to 3.0) | 6.8 (2.7 to 14.3) |
| 135 min | 4.0 (3.0 to 4.9) | 2.2 (2.1 to 2.3) | 2.6 (2.3 to 2.9) | 5.0 (1.2 to 12.1) | 3.8 (2.9 to 4.7) | 2.7 (2.7 to 2.7) | 2.6 (2.6 to 2.7) | 7.4 (2.7 to 16.5) |
| 150 min | 2.9 (2.9 to 3.0) | 7.8 (2.3 to 18.4) | 2.0 (1.4 to 2.6) | 5.0 (1.2 to 12.2) | 3.7 (2.9 to 4.4) | 2.6 (2.6 to 2.6) | 2.6 (2.5 to 2.7) | 7.0 (2.8 to 13.4) |
| 165 min | 3.1 (2.7 to 3.4) | 2.6 (2.1 to 3.7) | 2.6 (2.4 to 2.8) | 5.0 (1.1 to 12.0) | 4.6 (4.1 to 5.1) | 2.6 (2.6 to 2.6) | 2.6 (2.5 to 2.6) | 3.4 (2.6 to 4.1) |
| 180 min | 3.1 (2.9 to 3.4) | 2.1 (1.8 to 2.4) | 2.1 (1.4 to 2.7) | 4.8 (1.2 to 11.5) | 3.3 (2.7 to 3.9) | 2.6 (2.6 to 2.6) | 2.6 (2.5 to 2.6) | 3.2 (2.7 to 3.5) |
| 195 min | 3.8 (3.0 to 4.6) | 4.0 (1.8 to 8.3) | 2.5 (1.5 to 3.4) | 5.2 (1.1 to 12.8) | 3.8 (3.1 to 4.4) | 2.6 (2.6 to 2.6) | 2.6 (2.5 to 2.8) | 3.4 (2.7 to 4.5) |
| 210 min | 3.6 (3.1 to 4.2) | 4.0 (1.8 to 7.0) | 2.2 (1.9 to 2.4) | 4.8 (1.2 to 11.7) | 3.9 (2.9 to 4.9) | 2.8 (2.8 to 2.8) | 2.6 (2.5 to 2.7) | 6.3 (2.7 to 8.6) |
| 225 min | 3.4 (3.1 to 3.6) | 4.3 (1.7 to 9.1) | 1.9 (1.5 to 2.3) | 4.9 (1.1 to 12.0) | 3.1 (2.9 to 3.3) | 2.4 (2.4 to 2.4) | 2.6 (2.5 to 2.7) | 3.3 (2.7 to 4.0) |
| 240 min | 3.2 (3.0 to 3.5) | 3.9 (1.7 to 8.0) | 2.9 (1.4 to 4.3) | 7.4 (1.2 to 10.9) | 3.4 (2.6 to 4.2) | 2.6 (2.6 to 2.6) | 2.5 (2.5 to 2.6) | 5.3 (2.6 to 9.3) |
| 255 min | 3.1 (2.6 to 3.6) | 4.0 (1.6 to 8.7) | 8.5 (1.3 to 15.6) | 4.8 (1.1 to 11.8) | 3.8 (2.7 to 4.8) | 2.5 (2.5 to 2.5) | 2.9 (2.7 to 3.0) | 4.9 (2.7 to 9.1) |
| 270 min | 3.3 (3.2 to 3.4) | 4.4 (1.7 to 9.4) | 8.8 (1.9 to 15.6) | 5.0 (1.5 to 11.9) | 3.5 (2.5 to 4.4) | 2.7 (2.7 to 2.7) | 2.5 (2.4 to 2.6) | 4.8 (2.6 to 8.8) |
| 285 min | 2.9 (2.8 to 3.0) | 4.9 (2.0 to 10.7) | 1.9 (1.4 to 2.5) | 4.4 (1.2 to 10.4) | 2.8 (2.5 to 3.1) | 2.5 (2.5 to 2.5) | 2.6 (2.6 to 2.6) | 4.3 (2.7 to 7.6) |
| Subjects | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme |
|---|---|---|---|---|---|---|---|---|
| 1 attempt | 2 | 3 | 2 | 2 | 2 | 1 | 2 | 3 |
| 2 attempts | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| mL | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme |
|---|---|---|---|---|---|---|---|---|
| 5 min | 20.8 (20.7 to 20.8) | 21.4 (20.6 to 22.2) | 4.2 (4.2 to 4.2) | 3.8 (3.1 to 4.2) | 21.1 (21.1 to 21.1) | 20.7 (20.7 to 20.7) | 4.1 (4.1 to 4.1) | 4.1 (4.1 to 4.2) |
| 10 min | 41.2 (41.2 to 41.2) | 41.3 (39.6 to 42.9) | 11.7 (11.4 to 11.9) | 11.5 (10.4 to 12.3) | 42.0 (41.9 to 42.1) | 41.2 (41.2 to 41.2) | 12.1 (12.0 to 12.1) | 11.9 (11.8 to 12.1) |
| 60 min | 250 (249 to 250) | 249 (248 to 250) | 249 (248 to 249) | 240 (228 to 247) | 249 (247 to 250) | 249 (249 to 249) | 248 (247 to 248) | 246 (243 to 248) |
| 120 min | 448 (447 to 449) | 450 (448 to 452) | 449 (447 to 451) | 447 (447 to 448) | 449 (448 to 450) | 447 (447 to 447) | 448 (446 to 449) | 446 (441 to 448) |
| 180 min | 649 (647 to 650) | 650 (648 to 652) | 649 (647 to 651) | 647 (647 to 648) | 649 (648 to 650) | 647 (647 to 647) | 650 (649 to 650) | 646 (641 to 648) |
| 240 min | 848 (847 to 849) | 850 (848 to 853) | 849 (847 to 851) | 848 (847 to 849) | 849 (848 to 850) | 847 (847 to 847) | 847 (845 to 848) | 846 (841 to 848) |
| 285 min | 998 (995 to 1000) | 1000 (998 to 1002) | 999 (997 to 1000) | 997 (997 to 998) | 999 (998 to 1000) | 997 (997 to 997) | 997 (997 to 997) | 996 (991 to 998) |
Observed challenges, including catheter kinking, catheter/needle dislodgement/pull-out, infusion pump alarm, other technical problems
| participants | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme |
|---|---|---|---|---|---|---|---|---|
| Any Technical Challenge | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Catheter Kinking | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Occlusion Alarm | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Intervention Needed to Secure/Maintain Infusion | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 24 ga Catheter, Dose Flush, Single-step Rate Scheme | — | 0/2 (0%) | 2/2 (100%) |
| 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | — | 0/3 (0%) | 3/3 (100%) |
| 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | — | 0/3 (0%) | 3/3 (100%) |
| 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | — | 0/3 (0%) | 3/3 (100%) |
| 25 ga Needle, Dose Flush, Single-step Rate Scheme | — | 0/2 (0%) | 2/2 (100%) |
| 25 ga Needle, No Dose Flush, Single-step Rate Scheme | — | 0/2 (0%) | 2/2 (100%) |
| 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | — | 0/2 (0%) | 2/2 (100%) |
| 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme | — | 0/3 (0%) | 3/3 (100%) |
| Event | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme |
|---|---|---|---|---|---|---|---|---|
| Infusion site erythemaGeneral disorders | 2/2 | 3/3 | 3/3 | 3/3 | 2/2 | 2/2 | 2/2 | 2/2 |
| Infusion site painGeneral disorders | 2/2 | 3/3 | 2/3 | 2/3 | 2/2 | 0/2 | 2/2 | 2/3 |
| Infusion site rashGeneral disorders | 1/2 | 3/3 | 1/3 | 2/3 | 1/2 | 0/2 | 1/2 | 1/3 |
| Infusion site swellingGeneral disorders | 1/2 | 2/3 | 2/3 | 2/3 | 1/2 | 2/2 | 1/2 | 2/3 |
| Infusion site oedemaGeneral disorders | 1/2 | 2/3 | 1/3 | 1/3 | 1/2 | 0/2 | 1/2 | 1/3 |
| Infusion site pruritusGeneral disorders | 1/2 | 0/3 | 0/3 | 1/3 | 1/2 | 0/2 | 1/2 | 0/3 |
| DizzinessNervous system disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/2 | 0/2 | 1/2 | 1/3 |
| Hot flushVascular disorders | 0/2 | 0/3 | 1/3 | 0/3 | 0/2 | 0/2 | 1/2 | 0/3 |
| Age, Categorical(Participants) | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 20 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(years) | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 45.9 (33.5 to 58.3) | 32.6 (25.4 to 36.7) | 39.6 (21.4 to 50.0) | 29.3 (19.9 to 46.4) | 35.4 (20.3 to 50.5) | 39.7 (37.0 to 42.4) | 28.2 (24.1 to 32.3) | 20.9 (19.9 to 21.9) | 33.3 (19.9 to 58.3) |
| Sex: Female, Male(Participants) | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 12 |
| Male | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 3 | 8 |
| Region of Enrollment(participants) | 24 ga Catheter, Dose Flush, Single-step Rate Scheme | 24 ga Catheter, No Dose Flush, Single-step Rate Scheme | 24 ga Catheter, Dose Flush, Up-titrated Rate Scheme | 24 ga Catheter, No Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, Dose Flush, Single-step Rate Scheme | 25 ga Needle, No Dose Flush, Single-step Rate Scheme | 25 ga Needle, Dose Flush, Up-titrated Rate Scheme | 25 ga Needle, No Dose Flush, Up-titrated Rate Scheme | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 20 |
The record gives a start of May 2010, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)
Baxter Healthcare Corporation →